Subscribe
type here...
Subscribe

Tag: Promomed Group

The Medsintez Plant has launched a full-cycle production of hypoglycemic drugs for treating type II diabetes mellitus

Manufacturing Pharma -
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease.

PROMOMED obtained permission to produce drug product for diabetes mellitus Kvinsenta with semaglutide

Manufacturing Pharma -
The Russian government has published an order authorizing PROMOMED GROUP to use inventions protected by patents of the Danish company Novo Nordisk related to a drug product with semaglutide for the treatment of diabetes mellitus.

New product from Promomed Group for protection, ensure the functioning and repair of the nervous system cells

Manufacturing Pharma -
Promomed Group has registered a new drug Brainmax®, reaffirming its commitment to the strategy of launching innovative, knowledge-based products....

The new direct acting anticoagulant in the anticovid portfolio of Promomed Group

Manufacturing Pharma -
Promomed Group received marketing authorization certificate for a medicinal product with nadroparin calcium as active ingredient. Nadroparin is a...

Russian Ministry of Health included injectable Areplivir® in the guidelines for the treatment of COVID-19

Manufacturing Pharma -
The Ministry of Health of the Russian Federation has included the injectable form of the direct-acting antiviral drug Areplivir® (favipiravir)...

Biokhimik JSC of Promomed Group and Mordovia State University agreed on further cooperation

Drug Development Pharma -
At the meeting of the management of Biokhimik JSC with Acting Rector of the Ogarev Mordovia State University Dmitry...

M. Smagin: a competent system of joint planning of drugs procurements by the government and pharmaceutical business will eliminate possible shortages

Manufacturing Pharma -
In his speech at the «360 degree Pharmaceutical Supply» conference, Maxim Smagin, General Director of Promomed Group said: The...

Kira Zaslavskaya: we need joint and responsible work of all participants in the pharmaceutical market

Manufacturing Pharma -
«Vision and participation are essential to address global pharmaceutical safety challenges, including the fight against the pandemic. This means...

Efficacy of Areplivir (favipiravir) in the treatment of COVID-19 discussed at the 16th Russian Congress of Internal Medicine

Manufacturing Pharma -
On the first day of the 16th Russian Congress of Internal Medicine, Promomed Group organized a satellite symposium «Always...

The first Russian injectable drug for treatment of COVID-19 is ap-proved

Manufacturing Pharma -
The first Russian direct-acting intravenous antiviral drug Areplivir® (favipiravir) received marketing authorization certificate and its supply to hospitals in...

Revenue of PROMOMED DM LLC for 9 months of 2021 increased by 194.74% and amounted to RUB 13.25 bln.

Global Markets Pharma -
PROMOMED DM LLC publishes financial statements for 9 months of 2021 compiled in accordance with Russian Accounting Standards (RAS). According...

Promomed Group received approval for the first drug in its portfolio for treatment of HIV infection

Manufacturing Pharma -
Ritonavir, used for the treatment of HIV infection and viral hepatitis C, received the marketing authorization certificate and became...

PHARMPROM is a premier digital resource for the pharmaceutical sector, combining breaking news, deep insights, and key market events. We cover the entire product lifecycle—from R&D and manufacturing to distribution—in strict accordance with Good Pharmaceutical Practices (GxP).

Disclaimer All content on pharmprom.net is for informational purposes only and does not constitute medical advice. The materials are intended exclusively for industry professionals and are not addressed to the general public.

Company

Headlines

Roche Challenges Leaders: New Drug Shows 22.5% Weight Loss in 48 Weeks

0
Swiss pharmaceutical giant Roche published positive Phase II results...

Battle of Brands 2025: Rise of Russian Blockbusters and Fall of Old Giants

0
The Russian retail pharmaceutical market, which reached a volume...

Genetico Invests 50 Million Rubles in Development of Drugs for Heart Diseases

0
Genetico Center (part of the Artgen Biotech group) invests...

Petrovax Pharm Investments in Meningitis Vaccine Production Exceed 3 Billion Rubles

0
Biopharmaceutical company Petrovax Pharm has announced receiving an expanded...

Newsletter

Get important news delivered directly to your inbox and stay connected!

© PHARMPROM 2026